A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
Phase 2
Completed
NCT01797523
| Condition | Endometrial Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | M.D. Anderson Cancer Center |
|---|
| Status | Completed |
|---|
| Enrollment | 62 participants |
|---|
| Interventions | Metformin, Letrozole, Everolimus |
|---|
| Start date | Oct 7, 2013 |
|---|
| Completion date | Feb 4, 2026 |
|---|
| Results posted | Jul 30, 2026 |
|---|
Summary
The goal of this clinical research study is to learn if the combination of everolimus, letrozole, and metformin can help to control recurrent or progressive endometrial cancer. The safety of this drug combination will also be studied. Everolimus is designed to block a protein inside cancer cells that is involved in cancer growth. Letrozole is designed to block a protein from making estrogen. This may interfere with the growth of cancer cells. Metformin is commonly used to control blood sugar levels in patients with diabetes. It is designed to lower insulin levels, which may slow or stop the growth of endometrial cancer cells.
Clinical Benefit (CBR) Complete Response + Partial Response + Stable Disease Rates) Based on RECIST v1.1.
93 months · Participants
| Rad-Let-Met | 27 Participants |
|---|
| Rad-Let-Met | 15 Participants |
|---|
| Rad-Let-Met | 12 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.